Titan-dm studien Coala Life

Coala Life in collaboration with Region Gävleborg, Sweden, to run the TITAN-DM study on 500 patients with diabetes

Stockholm, October 7, 2021: Coala Life, a leading company in cloud-based remote monitoring of heart and lung diseases, is now conducting a clinical observational study in collaboration with researchers at the Gävleborg Region, Uppsala University and Karolinska Institute to increase knowledge about the incidence of atrial fibrillation in people with diabetes. The TITAN-DM study is expected to be completed in the spring of 2022 and a total of 500 people over the age of 65 will be included in the study.

The TITAN-DM study will include 500 patients who are recruited in collaboration with Swedish patient associations for people with diabetes. Recruitment, consent and instruction takes place digitally and via BankID approval, which enables study participants to participate regardless of where they live in Sweden. Each participant will receive a Coala Heart Monitor and be monitored remotely with ECG measurements in everyday life for three months.

“The study is unique in its kind where we will inventory the occurrence of atrial fibrillation in a group of patients with chronic disease and higher risk factors. By using Coala Heart Monitor and its healthcare platform, we can effectively follow a larger group of study participants at a distance for a longer period of time. The hypothesis is that we will find undetected cases of atrial fibrillation in this high-risk group of patients and thus be able to initiate preventive treatment and contribute to preventing the occurrence of stroke and its consequences “, states Peter Magnusson, heart specialist, Med Dr, working as chief physician in Region Gävleborg who is primarily responsible for the project.

People with diabetes have an increased risk of developing atrial fibrillation, a disease that increases the risk of stroke. Every year, stroke patients are cared for more than 1 million days in Swedish healthcare and even more days in care facilities after the hospital stay. No other diagnosis requires so many days of care or has such far-reaching consequences for the individual, family, healthcare and society, corresponding to costs of 20 billion per year, points out Michel Tagliati, doctor and project manager for the study.

“By allowing patients to use our technology in their own homes and follow them over a longer period of time, we’re once again pioneering Swedish healthcare,” concludes Dan Pitulia.

The study is approved by the Ethics Review Authority 2021-08-23, Dnr 2021-03323. You can read more about the study here: http://www.titan-dm.se